Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30508% above fair value
$196.79−10.01 (-4.84%)
Close on Nov 18, 2026Market cap $78.57BP/E –Yield –
Moderna Cases with job transfer or restriction by Year
Cases with job transfer or restriction (incidents)
Moderna Cases with job transfer or restriction: 2.00 incidents in FY2025, down 60.0% from a year earlier.
Latest, FY2025
2.00
Period ended Dec 31, 2025
Change on a year earlier
-60.0%
5.00 in FY2024
History
3 years
Since FY2023
Sources
1
2025 Impacting Human Health Report
Where the FY2025 figure comes from
“Job Transfer or Restriction(4) 1 5 2”
Source: 2025 Impacting Human Health Report ↗
Reported in Moderna 2025 Impacting Human Health Report.
annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cases with job transfer or restriction (incidents) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.00 | -60.0% | 2025 Impacting Human Health Report ↗ |
| FY2024 | Dec 31, 2024 | 5.00 | +400.0% | 2025 Impacting Human Health Report ↗ |
| FY2023 | Dec 31, 2023 | 1.00 | – | 2025 Impacting Human Health Report ↗ |
Cite this data
StockData. (2026). Moderna Cases with job transfer or restriction, annual FY2023–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/ehs-job-transfer
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.
See a number that looks wrong?